Hugues Barletta

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Sub-Urethral Tape Treatment of Female Urinary Incontinence?Morbidity Assessment of the Trans-Obturator Route and a New Tape (I-STOP): A Multi-Centre Experiment Involving 604 Cases

J.-S. Krauth, H RASOAMIARAMANANA, Hugues Barletta et al. · European Urology · 2004 · 86 citations

Medicine, Surgery, Urology +10

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France

Grégory Katz, Olivier Romano, Cyril Foa et al. · PLoS ONE · 2015 · 29 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17